Breaking Finance News

Enzo Biochem, Inc. (NYSE:ENZ) target price raised to $12.00, issued a report today by Zacks Investment Research

Enzo Biochem, Inc. (NYSE:ENZ) had its target price raised to $12.00 by Zacks Investment Research in an issued report announced 6/20/2017. The bumped up target suggests a possible upside of 0.11% based on the company's last stock close price.

Yesterday Enzo Biochem, Inc. (NYSE:ENZ) traded -0.73% lower at $10.80. The company’s 50-day moving average is $11.10 and its 200-day moving average is $9.70. The last stock close price is up 11.95% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 391,420 shares of the stock were exchanged, up from an average trading volume of 198,666

See Chart Below

Enzo Biochem, Inc. (NYSE:ENZ)

Enzo Biochem, Inc. has a 52 week low of $4.88 and a 52 week high of $12.04 with a P/E ratio of 15.23 The company’s market cap is currently $0.

About Enzo Biochem, Inc. (NYSE:ENZ)

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.